Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Qutenza after pre-treatment with lidocaine or tramadol in peripheral neuropathic pain
2010-023258-34Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of capsaicin in Peripheral neuropathic pain, postherpetic neuralgia (PHN) and peripheral nerve injury (PNI) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Primary tolerability variable. Started Mar 2011; status: completed.
02
Drugs
capsaicin
03
Conditions
Peripheral neuropathic painpostherpetic neuralgia (PHN)peripheral nerve injury (PNI)
Beyond the preview
Go deeper on 2010-023258-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023258-34.